Drug Search Results
More Filters [+]

BMS-986207

Alternative Names: bms-986207, bms986207, bms 986207
Latest Update: 2024-04-03
Latest Update Note: Clinical Trial Update

Product Description

A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, anti-TIGIT monoclonal antibody BMS-986207 binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-tigit-monoclonal-antibody-bms-986207)

Mechanisms of Action: TIGIT Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BMS-986207

Countries in Clinic: Argentina, Australia, Belgium, Canada, Chile, France, Germany, Israel, Italy, Japan, Poland, Romania, Singapore, Spain, Turkey, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 2: Multiple Myeloma|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Small Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CA020-002

P2

Completed

Non-Small-Cell Lung Cancer|Small Cell Lung Cancer

2024-01-25

45%

BMS-986207

P2

Active, not recruiting

Multiple Myeloma

2023-12-30

56%

CA020-016

P2

Completed

Non-Small-Cell Lung Cancer

2022-12-27

2021-000039-29

P2

Completed

Small Cell Lung Cancer

2022-12-27

Recent News Events